Ovarian Cancer Plasma Signature
Ovarian Cancer Detection
Discovery/ValidationActive Research
Key Facts
Indication
Ovarian Cancer Detection
Phase
Discovery/Validation
Status
Active Research
Company
About Olink Proteomics
Olink Proteomics was founded to overcome the limitations of traditional proteomics, providing a platform for accurate, high-throughput protein analysis. Its core Proximity Extension Assay (PEA) technology achieved widespread adoption in major academic and pharmaceutical research, culminating in its 2024 acquisition by Thermo Fisher Scientific. The company's strategy focuses on enabling the entire biomarker pipeline, from large-scale discovery to the development of validated clinical signatures, now amplified by Thermo Fisher's global commercial and R&D infrastructure.
View full company profile